PLX — Protalix Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $84.01m
- $80.63m
- $65.49m
- 22
- 79
- 56
- 51
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 17.8 | 18.3 | 39 | 17.1 | 23.6 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 4.7 | 2 | 3.44 | 4.59 | 5.27 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 32.5 | 55.7 | 61.7 | 44.9 | 69.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 10.9 | 10.4 | 9.92 | 9.64 | 10.9 |
Other Long Term Assets | |||||
Total Assets | 45.4 | 67.9 | 73.7 | 55.8 | 84.4 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 40.2 | 86.5 | 33.2 | 32.4 | 45.5 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 116 | 95 | 79.7 | 66.4 | 50.9 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | -70.3 | -27 | -6.04 | -10.6 | 33.6 |
Total Liabilities & Shareholders' Equity | 45.4 | 67.9 | 73.7 | 55.8 | 84.4 |
Total Common Shares Outstanding |